More Oncology Drugs Available In U.S., But Australians Pay 30% Less - Tufts Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The evidence-based approach adopted by Australia has led to lower prices, improving the affordability of those medications considered cost-effective for payers and patients by the reimbursement authority, the report says.